DRMA DRMA
Company Profile ↓Company Overview
DRMA (DRMA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -83.43% |
| 6 Months: | -36.41% |
| 3 Months: | -10.00% |
| 1 Month: | -17.02% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.37 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 83.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -792.79K | -540.06K | - | -2.26M | -1.33M | -1.71M | -2.79M | -2.73M | -2.45M | -2.28M | -1.73M | -1.81M | -3.20M | -2.88M | -3.23M | -2.34M | -1.77M | -1.76M | -1.93M |
| Net Income | -1.42M | -821.65K | -597.39K | -396.31K | -2.30M | -1.33M | -1.71M | -2.79M | -2.73M | -2.42M | -2.24M | -1.70M | -1.72M | -3.13M | -2.83M | -3.17M | -2.30M | -1.70M | -1.69M | -1.85M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.06 | -41.82 | -20.41 | -4.47 | -1.66 | -1.65 | -0.48 |
| R&D Expense | - | 411.95K | 120.47K | - | 680.59K | 867.20K | 799.78K | 1.60M | 1.61M | 1.55M | 1.19M | 838.93K | 902.98K | 1.60M | 2.01M | 2.40M | 1.28M | 617.84K | 504.39K | 383.72K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -3.17M | -7.86M | -9.67M | -8.04M | -12.51M | -7.77M |
| Net Income | -3.24M | -7.90M | -9.61M | -7.79M | -12.29M | -7.56M |
| Diluted EPS | - | - | - | -39.99 | -80.32 | -8.16 |
| R&D Expense | 1.61M | 3.46M | 5.65M | 4.07M | 8.20M | 2.93M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 605.45K | 11.62M | 6.94M | 7.98M | 3.53M | 7.86M |
| Total Equity | -210.16K | -3.18M | 10.11M | 6.02M | 6.36M | 1.56M | 6.22M |
| Cash & Equivalents | - | 530.40K | 10.80M | 6.24M | - | 3.16M | 7.52M |
| Total Liabilities | - | 3.78M | 1.52M | 922.63K | 1.62M | 1.97M | 1.64M |
| Current Liabilities | - | 3.78M | 1.52M | - | - | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.03M | -5.69M | -8.83M | -6.41M | -11.16M | -7.76M |
| Financing Cash Flow | 2.57M | 15.96M | 4.28M | 7.61M | 6.89M | 12.12M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 101.8% | -78.2% | -159.6% | -122.7% | -787.1% | -121.5% |
| ROCE % | 99.8% | -77.7% | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DRMA
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
- A new chapter in skincare has arrived - - This will be Dermata's first commercial product launch, planned for August 25, 2026 - - Join the waitlist at tomeskincare.com - SAN DIEGO, CA / ACCESS Newswire / August 5, 2026 / Dermata Therapeut…
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of …
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers - - The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with bot…
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome - - Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to s…
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA)(Nasdaq:DRMAW), a science-d…
Dermata Opens a New Chapter with the Release of Tome Skincare
-The oldest new thing in skincare - - Dermata expects to launch its first product in the middle of 2026 - SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"),…
DRMA — Frequently Asked Questions
What is the current share price of DRMA?
As of 2026-08-05 17:25 PDT, DRMA trades at $1.17 on NASDAQ/NYSE. Its 52-week range is $1.08 to $7.06.
What is the P/E ratio of DRMA?
DRMA trades at a trailing price-to-earnings (P/E) ratio of -0.14.
What is the return on equity (ROE) of DRMA?
DRMA has a return on equity (ROE) of -121.45%. Its return on capital employed (ROCE) is -122.48%.
Is DRMA a good stock to buy?
This page provides a data-driven analysis of DRMA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.